%0 Journal Article %A Prabhu S. Arunachalam %A Lilin Lai %A Hady Samaha %A Yupeng Feng %A Mengyun Hu %A Harold Sai-yin Hui %A Bushra Wali %A Madison Ellis %A Christopher Huerta %A Kareem Bechnack %A Sarah Bechnack %A Matthew Lee %A Matthew Litvack %A Cecilia Losada %A Alba Grifoni %A Alessandro Sette %A Veronika I. Zarnitsyna %A Nadine Rouphael %A Mehul S. Suthar %A Bali Pulendran %T Durability of immune responses to the booster mRNA vaccination against COVID-19 %D 2022 %R 10.1101/2022.12.02.22282921 %J medRxiv %P 2022.12.02.22282921 %X Waning immunity to vaccination represents a major challenge in vaccinology. Whether booster vaccination improves the durability of immune responses is unknown. Here we show, using a cohort of 55 adult vaccinees who received the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine against SARS-CoV-2, that a booster (i.e., 3rd immunization) dose at 6 - 10 months increased the half-life of serum neutralizing antibody (nAb) titers to 76 days from 56 - 66 days estimated after the primary two-dose vaccination series. A second booster dose (i.e., 4th immunization) more than a year after the primary vaccination increased the half-life further to 88 days. However, despite this modestly improved durability in nAb responses against the Wuhan strain, there was a loss in neutralization capacity against Omicron subvariants, especially the recently emerged variants, BA.2.75.2 and BQ.1.1 (35 and 50-fold drop in titers respectively, relative to the ancestral (WA.1) strain. While only 55 – 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (3rd dose), the response declined to below the detection limit in almost all individuals by 6 months. Notably, even against BA.1 and BA.5, the titers declined rapidly in a third of the vaccinees and were below the detection limit at 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months. Collectively, our data show that the durability of immune responses improves following subsequent booster immunizations; however, the emergence of immune evasive variants reduces the effectiveness of booster doses in preventing infection.Competing Interest StatementB.P. serves on the External Immunology Board of GlaxoSmithKline, and on the Scientific Advisory Board of Sanofi, Medicago, CircBio and Boehringer-Ingelheim. M.S.S. serves in a consulting role for Moderna and Ocugen. A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.Funding StatementThis study was supported by the NIH grants U19 AI057266 and U19 AI167903, Bill and Melinda Gates Foundation, Open Philanthropy, the Violetta L. Horton and Soffer Endowments, and contributions from an anonymous donor, to B.P. This work was supported in part by grants (NIH P51OD011132, 1U54CA260563, HHSN272201400004C, NIH/NIAID CEIRR under contract 75N93021C00017 to Emory University) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Woodruff Health Sciences Center 2020 COVID-19 CURE Award to M.S.S. Additional NIH support was provided under Contract No. 75N93021C00016 to A.G. and A.G. and U1 AI141995 and U19 AI118626 to A.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Emory University gave approval for this work (Study 00002061).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. %U https://www.medrxiv.org/content/medrxiv/early/2022/12/04/2022.12.02.22282921.full.pdf